Almac Group Executive to Speak at CTS East Asia Conference
November 28, 2016
|Global VP Quality Shares Expertise on Managing Biosimilar Products through Supply Chain|
|Craigavon, N.I., 28th November 2016 – Almac Group, the global contract pharmaceutical development and manufacturing organization, has announced that Paul O’Connor, Global VP Quality, Clinical Services, will speak at this years’ Clinical Trial Supply, East Asia conference, being held in Seoul, Korea from 30 November to 1 December.Mr. O’Connor’s presentation, entitled “Successfully managing Biosimilar products through the Clinical Supply Chain”, will take place at 14:00 on day one of the conference where he will share the platform with a growing list of industry experts from across the globe.During his talk, Paul will share his expertise and in-depth knowledge on a range of key considerations regarding biosimilars highlighting how their handling should be considered differently to other products. He will also review considerations for acquiring comparator compounds and packaging, labeling and release of these products. Paul also examines best practices for maintaining temperature control during transit and examines new shipping and monitoring solutions, alongside Supply Chain Management strategies that can be deployed to reduce overall cost and minimize product waste.
Paul has almost 25 years’ experience in the industry and is responsible for the global oversight of quality operations, procedures and processes throughout the Clinical Services business encompassing over 220 professional employees based in US, UK and Asia. In addition, he continues to act as a European Union Qualified Person (QP) for the organization, a post held by him for over 15 years. He holds a BSc First in Biochemical Sciences from Ulster University and is a renowned author of multiple published articles relating to quality matters.
Almac Clinical Services continue to serve the global Pharma and Biotechnology industries and have a significant presence within the APAC market, helping inform and shape the clinical trial infrastructure across all key clinical trial destinations.
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).